Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2013
At a glance
- Drugs BMS 929075 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Mar 2012 Planned end date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 03 Mar 2012 Planned initiation date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 07 Feb 2012 New trial record